Detecting Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma (LyMIC)

Description

Lymph node metastasis (LNM) is a major prognostic factor in intrahepatic cholangiocarcinoma (ICC), and accurate preoperative prediction of the presence or absence of LNM has significant clinical implications in determining treatment strategy. Despite this, there are currently no reliable biomarkers established to detect LNM in ICC. This study seeks to develop a liquid biopsy assay that can accurately detect LNM before treatment in ICC patients.

Conditions

Cholangiocarcinoma, Cholangiocarcinoma, Intrahepatic, Cholangiocarcinoma Resectable, Cholangiocarcinoma; Liver

Talk to us

Study Overview

On this page

Study Details

Study overview

Lymph node metastasis (LNM) is a major prognostic factor in intrahepatic cholangiocarcinoma (ICC), and accurate preoperative prediction of the presence or absence of LNM has significant clinical implications in determining treatment strategy. Despite this, there are currently no reliable biomarkers established to detect LNM in ICC. This study seeks to develop a liquid biopsy assay that can accurately detect LNM before treatment in ICC patients.

An Exosome-based Liquid Biopsy Signature for Pre-operative Identification of Lymph Node Metastasis in Patients With Intrahepatic Cholangiocarcinoma

Detecting Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma (LyMIC)

Condition
Cholangiocarcinoma
Intervention / Treatment

-

Contacts and Locations

Duarte

City of Hope Medical Center, Duarte, California, United States, 91016

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * A histologically confirmed diagnosis of intrahepatic cholangiocarcinoma.
  • * Received standard diagnostic and staging procedures as per local guidelines
  • * Availability of at least one blood-derived sample, drawn before receiving any curative-intent treatment
  • * Lack of or inability to provide informed consent
  • * Synchronous Intrahepatic cholangiocarcinoma and non- Intrahepatic cholangiocarcinoma diagnosed at or before surgery
  • * Secondary liver cancer

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

City of Hope Medical Center,

Ajay Goel, PhD, PRINCIPAL_INVESTIGATOR, City of Hope Medical Center

Study Record Dates

2026-06-18